23 November 2015

Under the reconfiguration of cancer services, certain haematology (blood disease) services – including transplant, leukaemia, lymphoma, myeloma and myeloproliferative neoplasms – are moving from the Royal Free Hospital to University College London Hospitals NHS Foundation Trust (UCLH).

With the transfer date set for the 1st December we are now less than two weeks away from the move, however with recent confirmation that the Junior Doctor Strike will take place on the 1st December (at 8am for 24 hours) the two Trusts will stagger the dates services move. On 1st December all patients will transfer from RFH to UCLH, including malignant haematology outpatient services. If the strike is not called off by the 12 noon on 27th November the malignant haematology inpatient transfer from 11South will instead take place on the 3rd December. If called off by this point, the inpatient transfer will remain on the 1st December.

The consultants, clinical nurse specialists (CNS’) and many of the other staff who primarily care for malignant haematology patients at the Royal Free Hospital will still transfer to UCLH on 1st December, with the expectation that the necessary medical staff will work cross-site in order to cover inpatient services until the 3rd December. Level 1 malignant haematology and all non-malignant services will remain at the Royal Free Hospital, and there will continue to be malignant haematology service provision at Barnet Hospital and Chase Farm Hospital sites.

19 November 2015

The prostate cancer team at University College Hospital has won a leading health industry award for innovation in diagnosing and treating prostate cancer.

The team targeted better diagnosis by taking a fresh look at the whole patient pathway, using methods that require fewer but more accurate biopsies. They also pioneered treatments – called focal therapy – that are cheaper, can be done in a day–case setting with quick recovery and carry significantly fewer long-term side-effects compared to traditional surgery or radiotherapy, such as incontinence and impotence. The new approach was shortlisted in the acute sector innovation category for the Health Service Journal Awards, and last night the team – accompanied by UCLH Chief Executive Sir Robert Naylor and Chairman Richard Murley – were named winners at the awards ceremony.

Professor Kathy Pritchard-Jones, Chief Medical Officer, London Cancer, said: “I am delighted to see the team at UCLH recognised for their efforts in improving care and services for patients with prostate cancer. We are already seeing improved outcomes and fewer complications for patients across the system, including helping partner trusts to provide these innovations in care closer to home for patients. This award is thoroughly well deserved.”

Earlier this year, the same team won the BMJ award for the Innovation category for the same work and were recently ‘highly commended’ by the NIHR for Surgical Research after being shortlisted for the NIHR CREST award.